| Chemical Properties | Back Directory | [Boiling point ]
880.9±75.0 °C(Predicted) | [density ]
1.30±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
Solid | [pka]
9.74±0.10(Predicted) | [color ]
Off-white to gray |
| Hazard Information | Back Directory | [Uses]
DB2313 is a potent inhibitor of transcription factor PU.1. DB2313 inhibits PU.1-dependent reporter gene transactivation with an IC50 of 5 μM. DB2313 disrupts the interaction of PU.1 with target gene promoters. DB2313 induces apoptosis in acute myeloid leukemia (AML) cells and has anticancer effects[1]. | [in vivo]
DB2313 (17 mg/kg; i.p.; three times per week; for 3 weeks) treatment decreases leukemia progression and results in increased survival in mice[1]. | Animal Model: | NSG mice bearing sublethally irradiated (2.0 Gy) and injection with PU.1 URE–/– AML cells[1] | | Dosage: | 17 mg/kg | | Administration: | Intraperitoneal injection; three times per week; for 3 weeks | | Result: | Decreased tumor burden and resulted in increased survival. |
| [storage]
Store at -20°C | [References]
[1] Iléana Antony-Debré, et al. Pharmacological inhibition of the transcription factor PU.1 in leukemia. J Clin Invest. 2017 Dec 1;127(12):4297-4313. DOI:10.1172/JCI92504
[2] Zhang S, Zhao S, Qi Y, et al. SPI1-induced downregulation of FTO promotes GBM progression by regulating pri-miR-10a processing in an m6A-dependent manner. Mol Ther Nucleic Acids. 2022;27:699-717. DOI:10.1016/j.omtn.2021.12.035 |
|
|